Exercise may shield hearts from chemo damage, new study hopes
NCT ID NCT04467411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a physical exercise program can prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. About 70 participants will be randomly assigned to exercise or usual care. Researchers will use heart scans and blood tests to see if exercise helps keep the heart healthy and to detect early warning signs of trouble.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- physical exercise intervention
- What this could lead to
- If successful, this could point toward a simple, drug-free way to protect the heart during breast cancer chemotherapy.
- What could go wrong
- This is a small, early-stage study (70 participants) focused on detecting early heart changes, not yet proving that exercise prevents heart failure. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2020
- Expected to finish
-
Aug 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Healthy volunteers and patients diagnosed with breast cancer who have been scheduled for the first cycle of anthracycline therapy.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A patient who has been diagnosed with breast cancer and has been scheduled for a first cycle of anthracycline therapy. * Participant who is willing and able to give informed consent for participation in the study. * Healthy (gender and age matched) volunteers willing to give informed consent for participation in the study. Exclusion Criteria: * Contraindication to magnetic resonance scanning such as an implantable cardiac device.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cardiac Research Office, Aberdeen Royal Infirmary
Aberdeen, Aberdeenshire, AB25 2ZD, United Kingdom
-
Cardiovascular Research Facility
Aberdeen, Aberdeenshire, AB25 2ZD, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?